Clinical significance of focal β-amyloid deposition measured by 18F-flutemetamol PET

Si Eun Kim1,2, Byungju Lee3, Seongbeom Park1,4,5, Soo Hyun Cho1,6, Seung Joo Kim1,7, Yeshin Kim8, Hyemin Jang1,4,5, Jee Hyang Jeong9, Soo Jin Yoon10, Kyung Won Park11, Eun-Joo Kim12, Na Yeon Jung13, Bora Yoon14, Jae-Won Jang8, Jin Yong Hong15, Jihye Hwang16, Duk L. Na1,4,5,17,18, Sang Won Seo1,4,5,19,20, Seong Hye Choi21* and Hee Jin Kim1,4,5*

Abstract

Background: Although amyloid PET of typical Alzheimer’s disease (AD) shows diffuse β-amyloid (Aβ) deposition, some patients show focal deposition. The clinical significance of this focal Aβ is not well understood. We examined the clinical significance of focal Aβ deposition in terms of cognition as well as Aβ and tau cerebrospinal fluid (CSF) levels. We further evaluated the order of Aβ accumulation by visual assessment.

Methods: We included 310 subjects (125 cognitively unimpaired, 125 mild cognitive impairment, and 60 AD dementia) from 9 referral centers. All patients underwent neuropsychological tests and 18F-flutemetamol (FMM) PET. Seventy-seven patients underwent CSF analysis. Each FMM scan was visually assessed in 10 regions (frontal, precuneus and posterior cingulate, lateral temporal, parietal, and striatum of each hemisphere) and was classified into three groups: No-FMM, Focal-FMM (FMM uptake in 1–9 regions), and Diffuse-FMM (FMM uptake in all 10 regions).

Results: 53/310 (17.1%) subjects were classified as Focal-FMM. The cognitive level of the Focal-FMM group was better than that of Diffuse-FMM group and worse than that of No-FMM group. Among the Focal-FMM group, those who had FMM uptake to a larger extent or in the striatum had worse cognitive levels. Compared to the Diffuse-FMM group, the Focal-FMM group had a less AD-like CSF profile (increased Aβ42 and decreased t-tau, t-tau/Aβ42). Among the Focal-FMM group, Aβ deposition was most frequently observed in the frontal (62.3%) and least frequently observed in the striatum (43.4%) and temporal (39.6%) regions.

Conclusions: We suggest that focal Aβ deposition is an intermediate stage between no Aβ and diffuse Aβ deposition. Furthermore, among patients with focal Aβ deposition, those who have Aβ to a larger extent and striatal involvement show clinical features close to diffuse Aβ deposition. Further longitudinal studies are needed to evaluate the disease progression of patients with focal Aβ deposition.

Keywords: β-amyloid, 18F-flutemetamol PET, Alzheimer’s disease, Cognition, Cerebrospinal fluid
Background
Alzheimer’s disease (AD), the most common cause of dementia, is characterized by β-amyloid (Aβ) and tau accumulation in the brain [1]. Aβ accumulation starts approximately 10 to 20 years before dementia symptoms begin. Thus, detecting the presence of Aβ is essential for early diagnosis of AD. With recent advances in detecting Aβ in vivo, the use of an Aβ biomarker is clinically available through PET imaging or CSF analysis [2, 3].

Although amyloid PET of typical AD shows diffuse Aβ deposition, some patients show focal Aβ deposition, the clinical significance of which is not well defined. Previous studies lack pathological examination results of patients with focal Aβ deposition on PET imaging. Brain Aβ burden on PET imaging may be quantitatively measured in the research field using standardized uptake value ratios (SUVR) and studies showed that higher SUVR is correlated with poor clinical outcome [4–6]. Meanwhile, in clinical practice, interpretation of amyloid PET relies on dichotomous visual rating (positive or negative). According to visual interpretation guidelines of PET images such as 18F-florbetaben or 18F-flutemetamol (FMM), if any of the brain regions (frontal, parietal, precuneus/posterior cingulate (PPC), lateral temporal lobes, and striatum) is positive in either hemisphere, the scan is considered to be positive [7, 8]. However, since Aβ deposition is a gradual process [9], a dichotomous visual rating may be misleading. Identifying the clinical significance of participants in the gray zone may help manage patients in clinical practice. Thus, this particular group needs to be well characterized.

In this study, we hypothesized that patients showing focal Aβ deposition have unique clinical characteristics. We examined patients showing focal Aβ deposition on FMM PET scan. We compared cognition and CSF AD biomarkers between patients with No-, Focal-, and Diffuse-FMM uptake. We also aimed to assess whether the extent and region of focal FMM uptake are related to cognition. We further evaluated the order of Aβ accumulation by visual assessment.

Methods
Participants
We recruited 310 patients with cognitively unimpaired (CU; n = 125), mild cognitive impairment (MCI; n = 125), and AD dementia (ADD, n = 60) who underwent FMM PET between June 2015 and December 2017. The CU individuals had normal age-, sex-, and education-adjusted performance on standardized cognitive tests [10]. The participants with MCI met the criteria proposed by Petersen et al. [11]: (1) subjective memory complaints, (2) relatively normal performance in other cognitive domains, (3) normal activities of daily living (ADL), (4) objective memory impairment below −1.5 SD on either verbal or visual memory tests, and (5) not demented. The ADD patients met the criteria for dementia by the Diagnostic and Statistical Manual of Mental Disorders 4th Edition, Text Revision (DSM-IV-TR) [12] and were diagnosed with probable ADD according to the NIA-AA core clinical criteria [1]. The patients were recruited from 9 referral hospitals in South Korea (175 from Samsung Medical Center, 135 from Validation Cohort of Korean Brain Aging Study for the Early Diagnosis and Prediction of AD (KBASE-V) [13]). All participants underwent neurologic examination, neuropsychological test, and Apolipoprotein E (APOE) genotyping. We screened blood tests including a complete blood count, blood chemistry, thyroid function, vitamin B12, folate, and syphilis serology and excluded participants with abnormal findings that could affect their cognition. Participants with previous or current neurological or psychiatric diseases such as brain tumors, encephalitis, epilepsy, and depressive disorders that could affect cognitive function were also excluded. On MRI, patients with structural lesions such as hydrocephalus, brain tumors, or traumatic brain injuries were also excluded.

The Institutional Review Boards approved this study at all participating centers. We obtained written, informed consent from patients and caregivers.

18F-flutemetamol PET acquisition and analysis
We performed FMM PET scans using a Discovery 600 PET/CT scanner (GE), Discovery 690 PET/CT scanner (GE), Discovery STE PET/CT scanner (GE), Biography MCT PET/CT scanner (Siemens) or Gemini TF PET/CT scanner (Philips) on a total number of 310 participants as described in a previous study [13]. The participants underwent a 20 min PET scan (4 × 5 min dynamic frames) starting at 90 min after intravenous injection of 185 MBq ± 10% of 18F-flutemetamol. Low-dose computed tomography was utilized for attenuation correction before scans. We reconstructed the images with the Ordered Subsets Expectation Maximization algorithm using 4 iterations and 16 subsets.

Blinded visual interpretation
Visual interpretation of the FMM PET images was performed by two blinded neurologists (referred to as “readers”) who successfully completed the manufacturing company’s electronic training program. Visual interpretation of FMM PET images was performed by systematic review of ten brain regions (frontal, parietal, PPC, striatum, and lateral temporal lobes in each hemisphere) [14]. For each region, the readers used dichotomous assessment in classifying images as either normal or abnormal in a rainbow color scale anchored to the pons. We defined each region to be abnormal when there was increased cortical gray matter signal (above 50–60% peak intensity)
and/or reduced (or absent) gray-white matter contrast [15]. Inter-reader agreement of interpretation of FMM PET was excellent (kappa score = 0.94).

We classified patients into three groups. No-FMM (no FMM uptake in any region), Focal-FMM (FMM uptake in 1–9 regions), and Diffuse-FMM (FMM uptake in all 10 regions). Examples of FMM PET images are shown in Additional file 1: Figure S1.

Cerebrospinal fluid collection, processing, and analysis
CSF sampling was performed in 77 participants (49 CU, 16 MCI, and 12 ADD) by procedures as previously described [13]. We obtained CSF in 15 mL polypropylene tubes (Falcon, Corning Science, NY, USA) and centrifuged at 2000xg for 10 min at room temperature (RT). Approximately 10 cc of the CSF supernatant was frozen and transferred to the laboratory at Inha University. For measuring CSF biomarkers, the CSF was thawed and gently extracted into pipettes with polypropylene tips. A total of 0.4 mL aliquots of CSF was frozen in polypropylene tubes (Sarstedt AG & Co., Nümbrecht, Germany) and stored at −80°C until analysis. We measured the level of CSF Aß 42, total tau (t-tau), and phosphorylated tau (p-tau) using the multiplex xMAP Lumineq platform with INNO-BIA AlzBio3 kits. AlzBio3 kits (Fujirebio Europe, Ghent, Belgium) contained capture monoclonal antibodies for Aß 42, t-tau, and p-tau, which linked to two aqueous quality controls (a-QC) with pre-defined concentration ranges for the three biomarkers. The procedure is described elsewhere [16, 17]. To reduce the effects of sources of variability on the results [18], CSF analysis was followed by the manufacturer’s instructions and standard of procedures that were previously described [19, 20].

Neuropsychological evaluation
All participants underwent a standardized neuropsychological battery called the Korean version of the Consortium to Establish a Registry for Alzheimer’s Disease Assessment Packet (CERAD-K) [21] or Seoul Neuropsychological Screening Battery (SNSB) [22], which consisted of tests of language, visuospatial, memory, and frontal/executive functions.

Tests in CERAD-K included the Korean version of the Boston Naming Test (K-BNT) to assess language function; constructional praxis (copying figures) to assess visuospatial function; 10 word list recall (20-min delayed recall) and constructional recall (20-min delayed figure recall) to assess verbal and visual memory, respectively; Controlled Oral Word Association Test (COWAT: animal naming) and Stroop Test (color reading) to assess frontal-executive function; and the Mini-Mental State Examination (MMSE) to assess global cognitive function.

Tests in SNSB included the K-BNT to assess language function; Rey-Osterrieth Complex Figure Test (RCFT: copying) to assess visuospatial function; Seoul Verbal Learning Test (20-min delayed recall) and RCFT (20-min delayed recall) to assess verbal and visual memory, respectively; COWAT (animal naming) and the Stroop Test (color reading) to assess frontal-executive function; and the MMSE to assess global cognitive function. [23]

Tests were conducted by experienced staff and supervised by board-certified neuropsychologists. The norms for each test were based on 1987 normal Korean participants (for CERAD-K) or 1067 normal Korean participants (for SNSB). In the analyses, we used the z-scores of each test, which were based on the mean and standard deviation of each measure in the age- and education-matched norms.

Statistical analysis
For descriptive statistics, we used the chi-square test and analysis of variance (ANOVA) followed by Bonferroni’s post hoc analyses.

To compare the cognitive profile of the three groups (No-FMM, Focal-FMM, and Diffuse-FMM group), we used ANOVA followed by Bonferroni’s post hoc analyses. When we compared the cognitive profile of the Regional-FMM group with the No-FMM or the Diffuse-FMM group, we used ANOVA followed by Bonferroni’s correction for 30 multiple tests (5 regions and 6 cognitive tests). To evaluate the association between cognition and number of FMM uptake regions, we used linear regression analyses.

For comparison of the CSF profile of the three groups, we used analysis of covariance (ANCOVA) followed by Bonferroni’s post hoc analyses after controlling for age. To evaluate the association between CSF profile and number of FMM uptake regions, linear regression analyses were used after adjusting for age. All statistical tests were performed using MedCalc (MedCalc Software version 19, Ostend, Belgium).

To determine the spreading order of FMM uptake, we assumed that regions with earlier appearance of pathology would show abnormal FMM uptake in a greater number of participants, as suggested by previous studies [24, 25]. The different frequency of regional involvement was assessed using a bootstrapping method with 1000 re-samples in R v3.1.3 (Institute for Statistics and Mathematics, Vienna, Austria; www.R-project.org), which derived the estimates of 95% confidence intervals and standard error. We calculated asymptotic p values and corrected for multiple comparisons with Bonferroni’s method for all combinations of regional pairs.

Results
Characteristics of the participants
The demographic and clinical characteristics are presented in Table 1. Of all the participants, 17.1% (53/310)
patients were classified into the Focal-FMM group. The proportion in the Focal-FMM group and the extent of Focal-FMM uptake differed according to cognitive level. 13.6% (17/125) of CU, 16.0% (20/125) of MCI, and 26.7% (16/60) of ADD were statistically significant differences in distribution of cognitive level across the groups.

**Cognitive profiles of Focal-FMM group**

Compared to the No-FMM group, the Focal-FMM group showed significantly lower performance in all cognitive domains except for visuospatial function. Compared to the Diffuse-FMM group, the Focal-FMM group showed better performance in verbal memory and visual memory functions. Global cognitive function (measured by MMSE) of the Focal-FMM group was better than the Diffuse-FMM group. Focal-FMM group with 1 to 5 regions involved showed better performance in all cognitive domains except for language when compared to the No-FMM group, while it showed better performance in all cognitive domains except for language when compared to Diffuse-FMM group. Focal-FMM group with 6–9 regions involved showed worse performance in all cognitive domains compared to No-FMM group, while it did not show significant difference when compared to Diffuse-FMM group (Additional file 1: Table S1).

Then, we compared each regional Focal-FMM group with the Focal- or Diffuse-FMM group to evaluate the regional effects of focal FMM uptake on cognitive function. Compared to the Diffuse-FMM group, verbal memory scores were higher in the Focal-FMM group with frontal, lateral temporal, parietal, or PPC regional involvement whereas no difference was found in the Focal-FMM group with striatal involvement. Compared to the Diffuse-FMM group, visual memory scores were higher in the Focal-FMM group with frontal, lateral temporal, or parietal regional involvement whereas no difference was found in the Focal-FMM group with PPC or striatal involvement. Compared to the No-FMM group, verbal and visual memory scores were lower in the Focal-FMM group with PPC or striatal involvement (Table 2).

Comparisons of cognitive scores between the No-, Focal-, and Diffuse-FMM groups in each cognitive level (CU, MCI and ADD) are shown in Additional file 1: Table S2. Among CU individuals, the cognitive score

**Table 1** Demographic characteristics of participants

|                           | No-FMM uptake (n = 174) | Focal-FMM uptake (n = 53) | Diffuse-FMM uptake (n = 83) | p No vs focal uptake | p No vs diffuse uptake | p Focal vs diffuse uptake |
|---------------------------|-------------------------|---------------------------|----------------------------|----------------------|------------------------|--------------------------|
| Age (mean ± SD)           | 69.4 ± 8.6              | 73.5 ± 7.9                | 71.4 ± 8.5                 | 0.008                | 0.253                  | 0.494                    |
| Men (%)                   | 73 (42.0)               | 15 (28.3)                 | 37 (44.6)                  | 0.075                | 0.692                  | 0.058                    |
| Education, years (mean ± SD) | 10.7 ± 5.0            | 10.3 ± 5.0                | 11.0 ± 4.5                 | 1.000                | 1.000                  | 1.000                    |
| APOE ε4 carrier (%)       | 21/166 (12.7)           | 23/53 (43.4)              | 42/81 (51.9)               | < 0.001              | < 0.001                | 0.340                    |
| Disease duration (months) | 62.5 ± 52.9             | 50.3 ± 44.5               | 41.5 ± 41.6                | 0.455                | 0.009                  | 1.000                    |
| Vascular risk factors     |                         |                           |                           |                      |                        |                          |
| Hypertension (%)          | 80 (46.0)               | 23 (43.4)                 | 29 (34.9)                  | 0.742                | 0.095                  | 0.324                    |
| Diabetes (%)              | 33 (19.0)               | 5 (9.4)                   | 11 (13.3)                  | 0.104                | 0.257                  | 0.502                    |
| Hyperlipidemia (%)        | 57 (32.8)               | 18 (34.0)                 | 11 (13.3)                  | 0.871                | 0.001                  | 0.004                    |
| Cognitive level           |                         |                           |                            |                      |                        |                          |
| CU (%)                    | 102 (58.6)              | 17 (32.1)                 | 6 (7.2)                    | < 0.001              | < 0.001                | < 0.001                  |
| MCI (%)                   | 64 (36.8)               | 20 (37.7)                 | 41 (49.4)                  |                      |                        |                          |
| ADD (%)                   | 8 (4.6)                 | 16 (30.2)                 | 36 (43.4)                  |                      |                        |                          |

*Abbreviations: FMM 18F-flutemetamol, APOE ε4 Apolipoprotein ε4, CU cognitively unimpaired, MCI mild cognitive impairment, ADD Alzheimer’s disease dementia.*
Table 2 Cognitive profile according to $^{18}$F-flutemetamol uptake regions

| Neuropsychological tests of cognitive domain | No-FMM uptake ($n=174$) | Focal-FMM uptake | Lateral temporal ($n=21$) | Parietal ($n=32$) | PPC ($n=32$) | Striatum ($n=23$) | Diffuse-FMM uptake ($n=83$) | No vs focal uptake | No vs diffuse uptake | Focal vs diffuse uptake |
|---------------------------------------------|--------------------------|------------------|--------------------------|------------------|-------------|------------------|--------------------------|-----------------------|----------------------|----------------------|
| Language                                    |                          |                  |                          |                  |             |                  |                          |                       |                      |                      |
| K-BNT                                       | $0.02 \pm 1.17$          | $-0.94 \pm 1.78$ | $-1.33 \pm 1.68^*$       | $-127 \pm 1.93$  | $-1.40 \pm 2.00^*$ | $-1.50 \pm 1.97^*$ | $-1.80 \pm 2.00^*$       | $-0.97 \pm 1.50$       | $<0.001$             | $<0.001$             | $1.000$              |
| Visuospatial                                |                          |                  |                          |                  |             |                  |                          |                       |                      |                      |                      |
| Figure copying                              | $-0.12 \pm 1.31$         | $-0.71 \pm 2.19$ | $-1.10 \pm 2.54$         | $-0.55 \pm 2.02$ | $-0.95 \pm 2.55$ | $-1.37 \pm 2.53$       | $-1.53 \pm 2.82$       | $-1.62 \pm 3.76$       | $0.324$              | $<0.001$             | $0.089$              |
| Memory                                      | $-0.46 \pm 1.26$         | $-0.97 \pm 1.26$ | $-1.12 \pm 1.19^*$       | $-0.97 \pm 1.31^*$| $-1.05 \pm 1.40^*$ | $-1.32 \pm 1.27^*$       | $-1.63 \pm 0.84^*$       | $-2.12 \pm 1.04$       | $0.020$              | $<0.001$             | $<0.001$             |
| Verbal memory                               | $-0.18 \pm 1.10$         | $-0.83 \pm 1.15$ | $-1.08 \pm 1.06^*$       | $-0.68 \pm 1.05^*$| $-0.93 \pm 1.19^*$ | $-1.09 \pm 1.21^*$       | $-1.34 \pm 1.08^*$       | $-1.77 \pm 0.96$       | $<0.001$             | $<0.001$             | $<0.001$             |
| Visual memory                               |                          |                  |                          |                  |             |                  |                          |                       |                      |                      |                      |
| Frontal/executive                           |                          |                  |                          |                  |             |                  |                          |                       |                      |                      |                      |
| COWAT                                       | $-0.07 \pm 1.10$         | $-0.78 \pm 1.11$ | $-0.98 \pm 1.08^*$       | $-1.09 \pm 1.02^*$| $-0.89 \pm 1.30^*$ | $-1.17 \pm 1.04^*$       | $-1.32 \pm 1.02^*$       | $-1.09 \pm 1.11$       | $<0.001$             | $<0.001$             | $0.331$              |
| Stroop test                                 | $-0.06 \pm 1.42$         | $-0.60 \pm 1.63$ | $-0.93 \pm 1.67$         | $-0.66 \pm 1.57$ | $-0.91 \pm 1.81$ | $-1.18 \pm 1.66^*$       | $-1.48 \pm 1.54^*$       | $-1.66 \pm 1.77$       | $0.080$              | $<0.001$             | $<0.001$             |
| Global                                      |                          |                  |                          |                  |             |                  |                          |                       |                      |                      |                      |
| MMSE                                        | $-0.31 \pm 1.35$         | $-1.13 \pm 2.46$ | $-1.65 \pm 2.80$         | $-1.04 \pm 1.86$ | $-1.35 \pm 2.86$ | $-1.85 \pm 2.84$        | $-2.24 \pm 3.21$        | $-2.57 \pm 2.98$       | $0.039$               | $<0.001$             | $<0.001$             |
| CDR-SB                                      | $0.80 \pm 1.04$          | $2.19 \pm 2.63$  | $2.94 \pm 2.82^*$        | $2.55 \pm 2.43$  | $2.50 \pm 2.87$ | $3.17 \pm 2.90^*$       | $3.52 \pm 3.18^*$       | $3.10 \pm 2.68$        | $<0.001$             | $<0.001$             | $0.024$              |

Values are mean z-scores of neuropsychological tests and raw score of CDR-SB (mean ± SD)

*p < 0.05 between regional Focal-FMM-uptake group and No-FMM-uptake group (after Bonferroni's correction for 5 regions and 6 cognitive tests)

Abbreviations: FMM $^{18}$F-flutemetamol, COWAT The Controlled Oral Word Association Test, K-BNT Korean version-Boston Naming Test, MMSE Mini-Mental State Exam, CDR-SB Clinical Dementia Rating Scale Sum of Boxes
did not differ among the No-, Focal-, and Diffuse-FMM groups. However, among MCI patients, the Focal-FMM group showed better performance in verbal and visual memory function, as well as in MMSE score, compared to the Diffuse-FMM group. Among ADD patients, Focal-FMM patients performed worse in language and frontal function compared to those of the No-FMM group and performed better in verbal memory than those of the Diffuse-FMM group. We provided a breakdown of cases by clinical designation and number of regions in Additional file 1: Table S3).

CSF amyloid and tau level of focal-FMM group
Levels of CSF AD biomarkers (Aβ 42, p-tau, t-tau, p-tau/ Aβ 42, and t-tau/ Aβ 42) in No-, Focal-, and Diffuse-FMM groups are shown in Fig. 2. The Focal-FMM group showed increased levels of CSF Aβ 42 and decreased levels of CSF t-tau and t-tau/Aβ 42, compared to the Diffuse-FMM group. However, there were no differences between Focal-FMM-uptake and No-FMM-uptake groups except for p-tau level.

Spreading order of FMM-uptake among focal-FMM-uptake group
Among the Focal-FMM group, Aβ deposition was most frequently observed in the frontal (62.3%, 95% CI = 48.8–75.8) followed by PPC (60.4%, 95% CI = 46.8–74.0), parietal (60.4%, 95% CI = 46.8–74.0), striatum (43.4%, 95% CI = 29.6–57.2), and lateral temporal (39.6%, 95% CI = 26.0–53.2) regions (Fig. 3).

Discussion
In this study, we investigated the clinical significance of patients with Focal-FMM uptake, which consisted of 17.1% of all participants. Our major findings were as follow. First, cognitive function of patients with Focal-FMM uptake was in the intermediate stage between patients with No- and Diffuse-FMM uptake. Among Focal-FMM patients, the larger extent and striatal involvement of FMM uptake was associated with worse cognition. Second, CSF AD biomarkers of Focal-FMM group were less AD-like compared to the Diffuse-FMM group. Finally, among the Focal-FMM group, FMM uptake was most frequently observed in the frontal and least observed in the striatum and lateral temporal regions. Taken together, our findings suggest that patients with Focal-FMM uptake have unique clinical characteristics. Furthermore, among patients with focal FMM uptake, those who have larger extent and striatal involvement of FMM showed clinical features close to diffuse Aβ uptake and, thus, might be considered as being in more advanced stage of AD.

We found that 17.1% of all participants had Focal-FMM uptake. Focal-FMM consisted substantial portion of participants in each cognitive level: 13.6% (17/125) of UC, 16.0% (20/125) of MCI, and 26.7% (16/60) of ADD. In clinical practice, interpretation of amyloid PET relies on visual assessment, which currently guides focal-FMM uptake to be read as positive for Aβ. However, the clinical significance of focal Aβ uptake is not well understood. Characterizing participants in this gray zone may help better manage patients.
Our first major finding was that cognitive function of patients with Focal-FMM was in the intermediate stage between patients with No- and Diffuse-FMM uptake. More importantly, the cognitive function differed according to the number and location of regions of focal FMM uptake. Among the Focal-FMM group, cognitive scores decreased with increasing number of FMM uptake regions. Our results are in line with previous studies using quantitative measurement of Aß burden [PiB [26–28], 18F-florbetapir [29], or FMM [30] SUVR]. Subjects with higher PiB SUVR showed lower scores on episodic memory tests [27]. Higher FMM SUVR correlated with lower delayed memory index [30], and higher 18F-florbetapir SUVR correlated with lower MMSE scores [30]. Among the Focal-FMM group, those who had FMM uptake in the striatum had the worst cognitive scores. Although there have been numerous studies on the associations between quantitative Aß deposition and cognition, no study has reported the association between visually assessed Aß deposition and cognitive profiles. As quantitative analysis is not widely used in clinical practice, studies on visual assessment is valuable for clinicians. Our results suggest that when managing patients showing focal FMM uptake, clinicians should consider the number and location of regions with focal Aß deposition.

Our second major finding was that patients with focal Aß deposition on PET showed less AD-like CSF profiles compared to the Diffuse-FMM group. In addition, the increased number of FMM uptake regions significantly correlated with CSF biomarker levels toward a more AD-like pattern (increased Aß42 and decreased t-tau, t-tau/ Aß42). Our results are consistent with previous studies showing negative correlation between CSF Aß42 levels and PET-based quantitative uptake of 18F-florbetapir [31] or 18F-florbetaben [32].

Our third major finding was the order of Aß accumulation. Among the Focal-FMM group, Aß deposition was most frequently observed in the frontal (62.3%) followed by the PPC (60.4%), parietal (60.4%), and least frequently observed in the striatum (43.4%) and lateral temporal (39.6%) regions. Unlike the Thal stage of amyloid deposition [9], our data showed that striatal involvement preceded the involvement of lateral temporal region. However, our result generally reflects a downward spreading pattern of Aß, suggesting that Aß deposits first in the cortex followed by subcortical structures [9].
Furthermore, our data revealed that, among Focal-FMM patients, those with subcortical Aβ involvement (striatum) showed lower cognition than those with cortical Aβ involvement (frontal, lateral temporal, parietal, and PPC). Our findings are concordant with those of previous studies which found that subcortical Aβ involvement, especially striatal Aβ, was related to worse cognitive performance and faster cognitive decline [33–35]. Patients with striatal involvement implies that they had higher Thal stage (Aβ phase 3) and thus are more likely to have tau. Therefore, we suggest that even when Aβ involvement is focal, Aβ deposition in the striatum might be a sign of possible worse clinical outcome.

However, the present study has some limitations. First, our study used a cross-sectional design and, therefore, we do not know the cognitive trajectory of participants. Further longitudinal studies are warranted to evaluate the disease progression rate of the Focal-FMM group. Second, we lack pathological data on Focal-FMM patients. Amyloid PET-negative MCI or dementia patients in our data might have vascular, hippocampal sclerosis, or other pathologies as the main etiology for cognitive impairment. Further studies that could exclude non-AD pathologies are necessary. Nevertheless, the strength of our current study is that we have identified the clinical significance of focal Aβ deposition, which comprised a substantial portion of participants in each cognitive level.

**Conclusions**

In the current study, we found that focal Aβ deposition has unique clinical characteristics that differ from patients with no or diffuse Aβ deposition. We suggest that focal Aβ deposition should be considered as an intermediate stage between no Aβ and diffuse Aβ deposition. In addition, when managing patients showing focal Aβ deposition, clinicians should consider the number and location of regions of focal Aβ deposition. Those with more regions involved, especially in the striatum, show clinical features close to diffuse Aβ deposition. Thus, cognitively unimpaired or MCI individuals with such signs might be more closely monitored for future cognitive decline. Further longitudinal studies are needed to evaluate the disease progression of patients with focal Aβ deposition.

**Supplementary information**

The online version of this article (https://doi.org/10.1186/s13195-019-0577-x) contains supplementary material, which is available to authorized users.

**Additional file 1: Table S1.** Cognitive profiles according to the number of 18F-flutemetamol uptake regions. **Table S2.** Cognitive profile of No-, Focal-, and Diffuse-FMM groups in each cognitive level. **Table S3.** Number of uptake regions in cognitively unimpaired, mild cognitive impairment, and Alzheimer's disease dementia. **Figure S1.** Examples of 18F-
Abbreviations
AD: Alzheimer’s disease; ADD: AD dementia; AB: B-amyloid; ANOVA: Analysis of variance; ANCOVA: Analysis of covariance; a-QC: Aqueous quality controls; CERAD-K: The Korean version of the Consortium to Establish a Registry for Alzheimer’s Disease Assessment Packet; COWAT: Controlled Oral Word Association Test; C J: Cognitively unimpaired; CDR-SB: Clinical Dementia Rating Scale Sum of Boxes; DSM-V-TR: Diagnostic and Statistical Manual of Mental Disorders 4th Edition, Text Revision; FMM: 18F-Flutemetamol; KBASE-V: Korean Brain Aging Study for the Early Diagnosis and Prediction of AD; K-BNT: Korean version-Boston Naming Test; MCI: Mild cognitive impairment; MMSE: Mini-Mental State Examination; PPC: Precuneus/posterior cingulate; p-tau: Phosphorylated tau; RCTF: Rey-Osterrieth Complex Figure Test; SUVR: Standardized uptake value ratios; SNSB: Seoul Neuropsychological Screening Battery; T-tau: Total tau

Acknowledgements
Not applicable.

Authors’ contribution
SEK, SCH, and HJK contributed to the conceptualization of the study, analysis and interpretation of data, and drafting. IL and SBP contributed to the analyses of imaging data and preparation of the figures and provided technical support. SHC, SJK, YK, HJ, JHJ, SJY, KWP, EJK, NYJ, and BY contributed to the data collection and interpretation of data. JJ, JYH, JH, DLN, and SWS contributed to the analysis and interpretation of data. All authors read and approved the final manuscript.

Funding
This research was supported by the Original Technology Research Program for Brain Science through the National Research Foundation of Korea (NRF) funded by the Korean government (MSIP) (No. 2014M3C7A1064752); by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP) (NRF-2018R1A1A30407925); and a grant of the Korean National Research Foundation of Korea (NRF) funded by the Korean government (MSIP) (No. 2014M3C7A1064752); by the for Brain Science through the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP) (NRF-2014R1A1A30407925); and a grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI18C1629 and HI18C0335).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The Institutional Review Board approved this study at all participating centers. We obtained written, informed consent from patients and caregivers.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 2Department of Neurology, Inje University College of Medicine, Haeundae Pahk Hospital, Busan, Korea. 3Department of Neurology, Yuseong Geriatric Rehabilitation Hospital, Pohang, Korea. 4Samsung Alzheimer Research Center, Samsung Medical Center, Seoul, Korea. 5Neuroscience Center, Samsung Medical Center, Seoul, Korea. 6Department of Neurology, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea. 7Department of Neurology, Gyeongsang National University School of Medicine and Gyeongsang National University Changwon Hospital, Changwon, Korea. 8Department of Neurology, Kangwon National University Hospital, Kangwon National University College of Medicine, Chuncheon, Korea. 9Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, Korea. 10Department of Neurology, Eulji University Hospital, Eulji University School of Medicine, Daejeon, Korea. 11Department of Neurology, Dong-A Medical Center, Dong-A University College of Medicine, Busan, Korea. 12Department of Neurology, Pusan National University Hospital, Pusan National University School of Medicine and Medical Research Institute, Busan, Korea. 13Department of Neurology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine and Research Institute for Convergence of Biomedical Science and Technology, Yangsan, Korea. 14Department of Neurology, Konyang University College of Medicine, Daejeon, Korea. 15Department of Neurology, Yonsei University Wonju College of Medicine, Wonju, Korea. 16Department of Neurology, Keimyung University Daegu Dongsan Hospital, Daegu, Korea. 17Department of Health Sciences and Technology, SAHST, Sungkyunkwan University, Seoul, Korea. 18STEM Cell & Regenerative Medicine Institute, Samsung Medical Center, Seoul, Korea. 19Department of Clinical Research and Evaluation, SAIHST, Sungkyunkwan University, Seoul, Korea. 20Center for Clinical Epidemiology, Samsung Medical Center, Seoul, Korea. 21Department of Neurology, Inha University School of Medicine, Incheon, Korea.

Received: 27 August 2019 Accepted: 23 December 2019

Published online: 04 January 2020

References
1. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.
2. Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:257–62.
3. Hong YJ, Park KW, Kang DY, Lee JH. Prediction of Alzheimer’s pathological changes in subjective cognitive decline using the self-report questionnaire and neuroimaging biomarkers. Dement Neurocogn Disord. 2019;18:19–29.
4. Thurfell L, Lilja J, Lundqvist R, Buckley C, Smith A, Vandenberghe R, et al. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads. J Nucl Med. 2014;55:1623–6.
5. Villeneuve VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourguet P, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69:181–92.
6. Rosenberg PB, Wong DF, Edell SL, Ross JS, Joshi AD, Brasic JR, et al. Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18AV-45 positron emission tomography. Am J Geriatr Psychiatry. 2013;21:272–8.
7. Bartelh H, Gertz HJ, Diesel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424–35.
8. Vox SB, van Boxtel MPI, Schieters OJG, Decker K, de Vugt M, Carriere I, et al. Modifiable risk factors for prevention of dementia in midlife, late life and the oldest-old: validation of the LIBRA index. J Alzheimers Dis. 2017;58:537–47.
9. Thal DR, Rub U, Olarites M, Bask H. Phases of a beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791–800.
10. Choi SH, Lee BH, Kim S, Hahn DS, Jeong JH, Yoon SJ, et al. Interchanging scores between clinical dementia rating scale and global deterioration scale. Alzheimer Dis Assoc Disord. 2003;17:98–105.
11. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 2000;57:507–15.
12. Diagnostic and Statistical Manual of Mental Disorders: DSM-V-TR. Washington, DC, USA: American Psychiatric Association; 2000.
13. Hwang J, Jeong JH, Yoon SJ, Park KW, Kim EJ, Yoon B, et al. Clinical and biomarker characteristics according to clinical spectrum of Alzheimer’s disease (AD) in the validation cohort of Korean brain aging study for the early diagnosis and prediction of AD. J Clin Med. 2019;8:341–59.
14. Farrar G. Regional visual read inspection of (18F) flutemetamol brain images from end-of-life and amnestic MCI subjects. J Nucl Med. 2017;58:1250.
other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2016. https://doi.org/10.1002/14651858.CD012216.

16. Olsson A, Vanderstichele H, Andreassen N, De Meyer G, Wallin A, Holmberg B, et al. Simultaneous measurement of beta-amyloid (1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem. 2005;51:339–45.

17. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403–13.

18. Kang JH, Korecka M, Toledo JB, Trojanowski JQ, Shaw LM. Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-beta (1-42) and tau proteins as Alzheimer disease biomarkers. Clin Chem. 2013;59:905–16.

19. Manu Vandijck RK, Waligorska T, De Smet S, Tsukie T, Verdoodt L, Deleersnijder W, Trojanowski J, Iwatsubo T, Shaw L. Inter-laboratory variation when using a unified test procedure for INNO-BIA AlzBio3. Alzheimer Dement. 2013;9:209–10.

20. Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol. 2011;121:597–609.

21. Lee JH, Lee KU, Lee DY, Kim KW, Jhoo JH, Kim JH, et al. Development of the Korean version of the consortium to establish a registry for Alzheimer’s disease assessment packet (CERAD-K): clinical and neuropsychological assessment batteries. J Gerontol B Psychol Sci Soc Sci. 2002;57:94–57.

22. Ahn HJ, Chin J, Park A, Lee BH, Suh MK, Seo SW, et al. Seoul neuropsychological screening battery-dementia version (SNSB-D): a useful tool for assessing and monitoring cognitive impairments in dementia patients. J Korean Med Sci. 2010;25:1071–6.

23. Kang SH, Park YH, Lee D, Kim JP, Chin J, Ahn Y, et al. The cortical Neuroanatomy related to specific neuropsychological deficits in Alzheimer’s continuum. Dement Neuropsychol. 2019;18:77–95.

24. Pike KE, Savage G, Villen magma VL, Ng S, Moss SA, Manuff P, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease. Brain. 2007;130:2837–44.

25. Grothe MJ, Barthel H, Sepulcre J, Dyrba M, Sabri O, Teipel SJ, et al. In vivo staging of regional amyloid deposition. Neurology. 2017;89:2031–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.